Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled trial of intravenous secukinumab in axial spondyloarthritis
2019-001177-90Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in axial spondyloarthritis (axSpA) comparing Intravenous secukinumab with Placebo (2 arms). Primary endpoint: ASAS40 response at Week 16. Started Oct 2019; status: completed.
02
Drugs
secukinumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2019-001177-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001177-90.